To include your compound in the COVID-19 Resource Center, submit it here.

Alirocumab: Additional Phase III data

Additional data from the double-blind, international Phase III ODYSSEY COMBO II trial in 720 patients with hypercholesterolemia and high cardiovascular risk who were not adequately controlled with

Read the full 273 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE